Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 82
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | ||
| NCT03860948 | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers | ||
| NCT04577963 | A Study of Fruquintinib in Combination with Tislelizumab in Advanced Solid Tumors | ||
| NCT05029635 | Phase III Study on HMPL-523 for Treatment of ITP | ||
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | ||
| NCT01955304 | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | ||
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | ||
| NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | ||
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT02105129 | A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 | ||
| NCT02601274 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | ||
| NCT01985555 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | ||
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | ||
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | ||
| NCT02017236 | A Food Effect Phase I Study of the Volitinib in Healthy Subjects | ||
| NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | ||
| NCT02691299 | A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | ||
| NCT03128164 | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | ||
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | ||
| NCT01882764 | HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis | ||
| NCT00659802 | Phase II Study of HMPL-004 in Patients With Ulcerative Colitis | ||
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | ||
| NCT03977090 | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | ||
| NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | ||
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | ||
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | ||
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | ||
| NCT02631642 | A Study of HMPL-689 in Healthy Volunteers | ||
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | ||
| NCT05173142 | HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors | ||
| NCT04755075 | Surufatinib Hepatic Impairment Study | ||
| NCT05509699 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | ||
| NCT03860532 | Phase I Clinical Trial in Healthy Male Volunteers | ||
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | ||
| NCT02689752 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib | ||
| NCT01645215 | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | ||
| NCT03483259 | To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers | ||
| NCT01805791 | A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis | ||
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | ||
| NCT04645940 | Fruquintinib Food Effect and Proton Pump Inhibitor Study | ||
| NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | ||
| NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | ||
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer |
